RT Journal Article
T1 Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
A1 Gray, Jhanelle E
A1 Villegas, Augusto
A1 Daniel, Davey
A1 Vicente, David
A1 Murakami, Shuji
A1 Hui, Rina
A1 Kurata, Takayasu
A1 Chiappori, Alberto
A1 Lee, Ki Hyeong
A1 Cho, Byoung Chul
A1 Planchard, David
A1 Paz-Ares, Luis
A1 Faivre-Finn, Corinne
A1 Vansteenkiste, Johan F
A1 Spigel, David R
A1 Wadsworth, Catherine
A1 Taboada, Maria
A1 Dennis, Phillip A
A1 Özgüroğlu, Mustafa
A1 Antonia, Scott J
K1 Durvalumab
K1 NSCLC
K1 Overall survival
K1 PACIFIC
K1 Three-year update
AB In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in the primary end points of progression-free survival (hazard ratio [HR] = 0.52, 95% confidence interval [CI]: 0.42-65, p  Patients, stratified by age, sex, and smoking history, were randomized (2:1) to receive durvalumab, 10 mg/kg intravenously every 2 weeks, or placebo for up to 12 months. OS was analyzed by using a stratified log-rank test in the intention-to-treat population. Medians and rates at 12, 24, and 36 months were estimated by the Kaplan-Meier method. As of January 31, 2019, 48.2% of patients had died (44.1% and 56.5% in the durvalumab and placebo groups, respectively). The median duration of follow-up was 33.3 months. The updated OS remained consistent with that previously reported (stratified HR = 0.69 [95% CI: 0.55-0.86]); the median OS was not reached with durvalumab but was 29.1 months with placebo. The 12-, 24- and 36-month OS rates with durvalumab and placebo were 83.1% versus 74.6%, 66.3% versus 55.3%, and 57.0% versus 43.5%, respectively. All secondary outcomes examined showed improvements consistent with previous analyses. Updated OS data from PACIFIC, including 3-year survival rates, demonstrate the long-term clinical benefit with durvalumab after chemoradiotherapy and further establish the PACIFIC regimen as the standard of care in this population.
YR 2019
FD 2019-10-14
LK http://hdl.handle.net/10668/14900
UL http://hdl.handle.net/10668/14900
LA en
DS RISalud
RD Apr 6, 2025